US becomes first country to approve Respiratory Syncytial Virus (RSV) vaccine

The US has approved the world’s first vaccine for Respiratory Syncytial Virus (RSV), with drugmaker GSK’s Arexvy being green-lighted for adults aged 60 and older. RSV is a common virus that can be serious for infants, the elderly, and those with weak immune systems. Other vaccine makers, including Pfizer and Moderna, are expected to follow soon. Rates of RSV and flu fell during COVID-19 lockdowns, but surged when restrictions were lifted, with young children hit hard.